Epitelyal Over Karsinomunda İntraperitoneal Kemoterapi sırasında oluşan Peritonovajinal Fistül

Yıl 2014, , 22 - 23, 21.08.2014

Umut Demirci Havva Yeşil Çınkır Bülent Yalçın

https://doi.org/10.5505/aot.2014.08208

Öz

Address for Correspondence: Uzm. Dr. Havva Yeşil Çınkır Ankara Onkoloji Hastanesi, Tıbbi Onkoloji Bölümü Ankara - Türkiye e-mail: [e-mail] Available at www.actaoncologicaturcica.com

Anahtar Kelimeler

İntraperitoneal tedavi; over neoplazmları; peritoneovajinal fistül

Peritoneovaginal Fistula during Intraperitoneal Chemotherapy of Epithelial Ovarian Carcinoma

Öz

chemotherapy showed 16-month OS advantage for optimally resected stage III EOC (1). However, catheter-related complications are common reasons (13-40%) for discontinuation of IP treatment. These are abdominal pain, bleeding, blockage, leakage, movement, malfunction, and/or access problems (2). Peritoneovaginal fistula is a rare complication of IP treatment, “leaky vaginal cuff” was the reason for discontinuation of treatment 2 of the 71 patients in a study (3). Although the significant improvement on survival, IP chemotherapy should be given carefully

Anahtar Kelimeler

Intraperitoneal treatment; ovarian neoplasms; peritoneovaginal fistula

Kaynakça

• Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal Cisplatin and Paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
• Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol. 2008;108:342-7
• Zeimet AG, Reimer D, Radl AC, et al. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res. 2009;29:2803-8.